RNTX Rein Therapeutics, Inc.
Financings ·
Rein received net proceeds of $0.95 million from the $1.0 million second advance on September 8, 2025. Yorkville buys each advance at 95% of face value, charges 8% interest and can require repayment in stock.
Rein Therapeutics, formerly Aileron, filed a late-filing notice for its 2024 annual report and expects an impairment loss of about $37.0 million tied to a delay in developing LTI-01. The charge is non-cash, but the company's 2023 annual report already carried a going-concern warning.
The impairment follows a temporary delay of further clinical work on LTI-01. The company, formerly Aileron Therapeutics, needs more time to finish its impairment assessment.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $11.0 million | $14.2 million |
| Net income (loss) | -$49.9 million | -$62.9 million |
| Cash from operations | -$19.4 million | -$22.3 million |
| Cash and equivalents | $3.2 million | $12.9 million |
| Short-term investments | $0 |
Our latest story on this, dated Mar 31, 2025: "Rein Therapeutics, formerly Aileron, files NT 10-K and expects $37.0 million impairment". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Mar 31, 2025: "Rein Therapeutics, formerly Aileron, files NT 10-K and expects $37.0 million impairment". The story links the filing or release it is based on. Read the story.
Rein Therapeutics, Inc. trades under the ticker RNTX on NASDAQ.
Rein Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Rein Therapeutics, Inc. is 1420565. Its filings are on SEC EDGAR.
86,267,032 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Rein Therapeutics, Inc. under United States.
Our directory classifies Rein Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Rein Therapeutics, Inc. is US00887A2042.
aibio.space lists Rein Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Rein Therapeutics, Inc. reported a net loss of $49.9 million for the fiscal year ended Dec 31, 2025, and used $19.4 million of cash in operations, per its annual report to the SEC.
$11.0 million in the fiscal year ended Dec 31, 2025, per its annual report.
$40.6 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on Rein Therapeutics, dated Sep 9, 2025: "Rein Therapeutics draws second $1.0 million advance from Yorkville". Rein received net proceeds of $0.95 million from the $1.0 million second advance on September 8, 2025. Yorkville buys each advance at 95% of face value, charges 8% interest and can require repayment in stock. Source.
Our latest financing story, dated Sep 9, 2025: "Rein Therapeutics draws second $1.0 million advance from Yorkville". Rein received net proceeds of $0.95 million from the $1.0 million second advance on September 8, 2025. Yorkville buys each advance at 95% of face value, charges 8% interest and can require repayment in stock. Source.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a financing. SEC Form S-1. Source
Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,9.01). Source
Reported an unregistered sale of its securities. SEC Form 424B5. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio